On Monday Acrivon Therapeutics Inc (NASDAQ: ACRV) opened higher 17.09% from the last session, before settling in for the closing price of $1.99. Price fluctuations for ACRV have ranged from $1.05 to $8.74 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -74.96% annually for the last half of the decade. Company’s average yearly earnings per share was noted 6.77% at the time writing. With a float of $22.31 million, this company’s outstanding shares have now reached $31.45 million.
Acrivon Therapeutics Inc (ACRV) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Acrivon Therapeutics Inc is 29.07%, while institutional ownership is 48.63%. The most recent insider transaction that took place on Apr 30 ’25, was worth 617,412. In this transaction 10% Owner of this company sold 437,881 shares at a rate of $1.41, taking the stock ownership to the 3,403,025 shares. Before that another transaction happened on May 01 ’25, when Company’s 10% Owner sold 298,886 for $1.34, making the entire transaction worth $400,507. This insider now owns 3,104,139 shares in total.
Acrivon Therapeutics Inc (ACRV) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.59 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.59) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.18% during the next five years compared to -74.96% drop over the previous five years of trading.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
Check out the current performance indicators for Acrivon Therapeutics Inc (ACRV). In the past quarter, the stock posted a quick ratio of 10.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.25, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -2.15 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Let’s dig in a bit further. During the last 5-days, its volume was 2.86 million. That was better than the volume of 0.77 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.92%.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 77.63%, which indicates a significant decrease from 81.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1500 in the past 14 days, which was higher than the 0.1200 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7200, while its 200-day Moving Average is $2.4300. However, in the short run, Acrivon Therapeutics Inc’s stock first resistance to watch stands at $2.4800. Second resistance stands at $2.6400. The third major resistance level sits at $2.8100. If the price goes on to break the first support level at $2.1500, it is likely to go to the next support level at $1.9800. The third support level lies at $1.8200 if the price breaches the second support level.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
There are currently 31,456K shares outstanding in the company with a market cap of 73.30 million. Presently, the company’s annual sales total 0 K according to its annual income of -80,560 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -21,010 K.
